Preferred Label : Fisogatinib;
NCIt synonyms : Fibroblast Growth Factor Receptor 4 Inhibitor BLU-554; N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide; 2-Propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)-;
NCIt definition : An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4),
with potential antineoplastic activity. Upon oral administration, fisogatinib specifically
binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation
of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell
proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and
is involved in tumor cell proliferation, differentiation, angiogenesis, and survival.
FGF19 is overexpressed by certain tumor cell types.;
UNII : 5Q7R99CKV2;
InChIKey : MGZKYOAQVGSSGC-DLBZAZTESA-N;
CAS number : 1707289-21-1;
Molecule name : BLU-554; CS-3008; CS 3008; BLU 554;
NCI Metathesaurus CUI : CL498220;
Origin ID : C123826;
UMLS CUI : C5235382;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
